Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D).
Clinicaltrials.gov Number: NCT04509791, https://clinicaltrials.gov/ct2/show/NCT04509791
EudraCT Number: 2019-003265-17 https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-003265-17/BE
Aim: The drug ATG (Anti Thymocyte Globulin) will be tested over 12 months in adolescents to adults (12-25 years for now, soon to be followed by 5 to 25 years, n=114). ATG, given once in a two days infusion regimen, is a drug recently shown to be able to keep the balance between attacking and regulating cells within the immune system, and thereby helping to preserve insulin secretion. Defining the minimal effective dose of ATG treatment is one aim of the study.